Literature DB >> 18528739

Hypoxia markers in human osteosarcoma: an exploratory study.

Hiroo Mizobuchi1, José Manuel García-Castellano, Shaji Philip, John H Healey, Richard Gorlick.   

Abstract

Neoplastic cells growing under hypoxic conditions exhibit a more aggressive phenotype by activating a cascade of molecular events partly mediated by hypoxia-inducible transcription factor (HIF-1alpha) and vascular endothelial growth factor (VEGF). The roles of these markers have been studied previously in several cancer lines. We ascertained the frequency of HIF-1alpha expression, VEGF expression, the degree of neovascularization, and cell proliferation in osteosarcoma samples. Samples from osteosarcoma patients were assessed for HIF-1alpha and VEGF protein expression using immunohistochemistry, neovascularization using antibodies for Factor VIII, and cell proliferation using the Ki-67 labeling index. Associations between these parameters and clinical features were examined. HIF-1alpha staining was positive in 35% of patients and metastases were present in 61% of these HIF-1alpha-positive patients. VEGF protein expression was detected in 69% of patients, 92% of whom were female. We observed an insignificant trend for a higher frequency of VEGF expression in the high-grade as compared to low-grade osteosarcoma. We observed no association between vascular density and proliferation index and any clinical parameters. We found an association between HIF-1alpha expression and metastatic disease and between VEGF expression and female gender.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528739      PMCID: PMC2493019          DOI: 10.1007/s11999-008-0328-y

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  51 in total

1.  Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma in situ.

Authors:  C Grau; J Overgaard
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins.

Authors:  K M Pan; M Baldwin; J Nguyen; M Gasset; A Serban; D Groth; I Mehlhorn; Z Huang; R J Fletterick; F E Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

3.  Histological and immunohistochemical prediction for local control of cervical squamous cell carcinoma treated with radiotherapy alone.

Authors:  T Nakano; K Oka; T Arai
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-10       Impact factor: 7.038

4.  Tumor proliferation in rectal cancer following preoperative irradiation.

Authors:  C G Willett; G Warland; M P Hagan; W J Daly; J Coen; P C Shellito; C C Compton
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

5.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix.

Authors:  M Höckel; C Knoop; K Schlenger; B Vorndran; E Baussmann; M Mitze; P G Knapstein; P Vaupel
Journal:  Radiother Oncol       Date:  1993-01       Impact factor: 6.280

6.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

7.  The labelling index in carcinoma of the uterine cervix: its correlation with tumour sterilization.

Authors:  J L Lagrange; A Courdi; P Chauvel; J Gioanni; F Ettore; A Bongain; T Duforestel; J Y Gillet
Journal:  Br J Radiol       Date:  1992-01       Impact factor: 3.039

Review 8.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

9.  Proliferation measurements with flow cytometry Tpot in cancer of the uterine cervix: correlation between two laboratories and preliminary clinical results.

Authors:  R W Tsang; A W Fyles; P Kirkbride; W Levin; L A Manchul; M F Milosevic; G A Rawlings; D Banerjee; M Pintilie; G D Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-30       Impact factor: 7.038

10.  Carcinoma of the cervix uteri: an assessment of the relationship of tumour proliferation to prognosis.

Authors:  D J Cole; D C Brown; E Crossley; C J Alcock; K C Gatter
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640

View more
  34 in total

1.  Effects of vascular endothelial growth factor expression on pathological characteristics and prognosis of osteosarcoma.

Authors:  Gang Han; Yan Wang; Wenzhi Bi; Jinpeng Jia; Wei Wang; Meng Xu
Journal:  Clin Exp Med       Date:  2015-08-29       Impact factor: 3.984

2.  Microvesicles derived from human bone marrow mesenchymal stem cells promote U2OS cell growth under hypoxia: the role of PI3K/AKT and HIF-1α.

Authors:  Shanshan Lin; Bo Zhu; Guozhi Huang; Qing Zeng; Chuhuai Wang
Journal:  Hum Cell       Date:  2018-11-30       Impact factor: 4.174

3.  Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.

Authors:  Jilong Yang; Da Yang; Yan Sun; Baocun Sun; Guowen Wang; Jonathan C Trent; Dejka M Araujo; Kexin Chen; Wei Zhang
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

4.  Tip110 Regulates the Cross Talk between p53 and Hypoxia-Inducible Factor 1α under Hypoxia and Promotes Survival of Cancer Cells.

Authors:  Khalid Amine Timani; Ying Liu; Yan Fan; Khalid S Mohammad; Johnny J He
Journal:  Mol Cell Biol       Date:  2015-05-04       Impact factor: 4.272

Review 5.  A central role for hypoxic signaling in cartilage, bone, and hematopoiesis.

Authors:  Erinn B Rankin; Amato J Giaccia; Ernestina Schipani
Journal:  Curr Osteoporos Rep       Date:  2011-06       Impact factor: 5.096

6.  Clinical significance of hypoxia-inducible factor 1 and VEGF-A in osteosarcoma.

Authors:  Huanli Zhao; Yuhui Wu; Yang Chen; Hongmei Liu
Journal:  Int J Clin Oncol       Date:  2015-06-16       Impact factor: 3.402

7.  Predicting chemosensitivity in osteosarcoma prior to chemotherapy: An investigational study of biomarkers with immunohistochemistry.

Authors:  Yong Chen; Yun Yang; Zhanna Yuan; Chunmeng Wang; Yingqiang Shi
Journal:  Oncol Lett       Date:  2012-02-10       Impact factor: 2.967

Review 8.  Hypoxia, stem cells and bone tumor.

Authors:  Wen Zeng; Rong Wan; Yuehuan Zheng; Shree Ram Singh; Yiyong Wei
Journal:  Cancer Lett       Date:  2011-09-29       Impact factor: 8.679

9.  A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation.

Authors:  Jason Glover; Mark Krailo; Tanya Tello; Neyssa Marina; Katherine Janeway; Don Barkauskas; Timothy M Fan; Richard Gorlick; Chand Khanna
Journal:  Pediatr Blood Cancer       Date:  2014-12-08       Impact factor: 3.167

10.  Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis.

Authors:  Barbara Rossi; Giovanni Schinzari; Giulio Maccauro; Laura Scaramuzzo; Diego Signorelli; Michele A Rosa; Carlo Fabbriciani; Barone Carlo
Journal:  BMC Musculoskelet Disord       Date:  2010-02-16       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.